Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
James Song, MD, FAAD, discusses how emerging topical JAK inhibitors like ruxolitinib cream may reduce the necessity for systemic therapies in select pediatric atopic dermatitis patients by effectively controlling moderate disease and potentially serving as long-term maintenance therapy with a favorable safety profile.
James Song, MD, FAAD, discusses how clinicians should evaluate treatment response based on objective measures including BSA involvement, EASI scores, and pruritus ratings when determining whether to escalate from topical ruxolitinib to systemic therapy or de-escalate to maintenance treatment in pediatric atopic dermatitis patients.
James Song, MD, FAAD, discusses how topical Janus kinase inhibitors offer distinct advantages for children with moderate atopic dermatitis by providing effective inflammation control without the adverse effects of topical corticosteroids, particularly in sensitive areas like the face and intertriginous regions.
James Song, MD, FAAD, discusses how ruxolitinib cream addresses a significant treatment gap in pediatric atopic dermatitis by providing a non-steroidal topical option with efficacy comparable to medium-potency corticosteroids but without the associated safety concerns.
Panelists discuss how data from head-to-head clinical trials comparing different therapeutic options in atopic dermatitis inform treatment decisions while exploring critical gaps in research that future studies need to address.
Panelists discuss how head-to-head trials in psoriasis provide direct efficacy and safety comparisons between IL-17 inhibitors and other drug classes. Studies like BE RADIANT, BE VIVID, and IXORA-R highlight bimekizumab’s and ixekizumab’s superiority over secukinumab and ustekinumab. CLARITY and COBRA compare IL-17 to IL-23 inhibitors, while IMMerge and BE BOLD explore risankizumab’s role. These trials inform treatment decisions by guiding biologic selection based on efficacy, durability, and safety.
James Song, MD, FAAD, discusses how the treatment of pediatric atopic dermatitis (AD) demands personalized consideration of disease severity, patient age, affected areas, and treatment history. Ruxolitinib cream may address gaps by providing a nonsteroidal alternative with fewer adverse effects, potentially delaying or reducing systemic therapy needs.
Haut.AI’s new tool promotes inclusive and realistic conversations on the power of skincare products, according to the CEO.
Eichenfield discusses high skin clearance and safety in teens with psoriasis, per new ICONIC-LEAD phase 3 data.
Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.
Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.
Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimab’s efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.
Untreated or undertreated AD can lead to poor sleep, infections, and stunted development.
Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumab’s 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumab’s 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.
Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.
Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 2–11, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.
Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.
Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.
Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.
Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.
Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.
An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patient’s GEP risk level would influence the approach to surveillance and follow-up.
For Rosacea Awareness Month, Zoe Diana Draelos, MD, spoke to Dermatology Times about skinbetter’s Mystro Active Balance Serum and its NRS Seal of Acceptance.
Raj Chovatiya, MD, PhD, MSCI, discusses his approach to diagnosing and treating chronic hand eczema.
Treatment decisions are increasingly guided by patient values, preferences, and quality-of-life considerations.
Panelists discuss how prior and current treatments for patients with generalized pustular psoriasis (GPP) have evolved from traditional systemic therapies with significant limitations to newer targeted biologics and small molecules that specifically address the underlying IL-36 pathway dysregulation, offering improved efficacy and safety profiles for this rare but severe condition.
Panelists discuss how recognizing the flares and triggers of generalized pustular psoriasis requires vigilant monitoring for warning signs such as fever, malaise, and spreading erythema, while understanding that common precipitating factors include medication withdrawals, infections, pregnancy, and certain drugs that can rapidly transform stable disease into acute, potentially life-threatening episodes requiring immediate intervention.
Current JAK inhibitors are approved only for those 12 and older, leaving younger patients without access.
